Seroatlas · Human Serome Atlas

SDK2

Protein sidekick-2

Also known as: FLJ10832, KIAA1514, SDK2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q58EX2
Gene: SDK2
Ensembl: ENSG00000069188
Chromosome: 17
Canonical length: 2172 aa
Protein class: Predicted membrane proteins
Quaternary structure: Homodimer

OverviewNCBI Gene

The protein encoded by this gene is a member of the immunoglobulin superfamily. The protein contains two immunoglobulin domains and thirteen fibronectin type III domains. Fibronectin type III domains are present in both extracellular and intracellular proteins and tandem repeats are known to contain binding sites for DNA, heparin and the cell surface. This protein, and a homologous mouse sequence, are very similar to the Drosophila sidekick gene product but the specific function of this superfamily member is not yet known. Evidence for alternative splicing at this gene locus has been observed but the full-length nature of additional variants has not yet been determined. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

2172 residues, UniProt reviewed canonical sequence.

>Q58EX2|SDK2
     1  MWGLLIWTLL ALHQIRAARA QDDVSPYFKT EPVRTQVHLE GNRLVLTCMA EGSWPLEFKW
    61  LHNNRELTKF SLEYRYMITS LDRTHAGFYR CIVRNRMGAL LQRQTEVQVA YMGSFEEGEK
   121  HQSVSHGEAA VIRAPRIASF PQPQVTWFRD GRKIPPSSRI AITLENTLVI LSTVAPDAGR
   181  YYVQAVNDKN GDNKTSQPIT LTVENVGGPA DPIAPTIIIP PKNTSVVAGT SEVTLECVAN
   241  ARPLIKLHII WKKDGVLLSG GISDHNRRLT IPNPTGSDAG YYECEAVLRS SSVPSVVRGA
   301  YLSVLEPPQF VKEPERHITA EMEKVVDIPC QAKGVPPPSI TWYKDAAVVE VEKLTRFRQR
   361  NDGGLQISGL VPDDTGMFQC FARNAAGEVQ TSTYLAVTSI APNITRGPLD STVIDGMSVV
   421  LACETSGAPR PAITWQKGER ILASGSVQLP RFTPLESGSL LISPTHISDA GTYTCLATNS
   481  RGVDEASADL VVWARTRITK PPQDQSVIKG TQASMVCGVT HDPRVTIRYI WEKDGATLGT
   541  ESHPRIRLDR NGSLHISQTW SGDIGTYTCR VISAGGNDSR SAHLRVRQLP HAPEHPVATL
   601  STVERRAINL TWTKPFDGNS PLIRYILEMS ENNAPWTVLL ASVDPKATSV TVKGLVPARS
   661  YQFRLCAVND VGKGQFSKDT ERVSLPEEPP TAPPQNVIAS GRTNQSIMIQ WQPPPESHQN
   721  GILKGYIIRY CLAGLPVGYQ FKNITDADVN NLLLEDLIIW TNYEIEVAAY NSAGLGVYSS
   781  KVTEWTLQGV PTVPPGNVHA EATNSTTIRF TWNAPSPQFI NGINQGYKLI AWEPEQEEEV
   841  TMVTARPNFQ DSIHVGFVSG LKKFTEYFTS VLCFTTPGDG PRSTPQLVRT HEDVPGPVGH
   901  LSFSEILDTS LKVSWQEPGE KNGILTGYRI SWEEYNRTNT RVTHYLPNVT LEYRVTGLTA
   961  LTTYTIEVAA MTSKGQGQVS ASTISSGVPP ELPGPPTNLG ISNIGPRSVT LQFRPGYDGK
  1021  TSISRWLVEA QVGVVGEGEE WLLIHQLSNE PDARSMEVPD LNPFTCYSFR MRQVNIVGTS
  1081  PPSQPSRKIQ TLQAPPDMAP ANVSLRTASE TSLWLRWMPL PEMEYNGNPE SVGYKIKYSR
  1141  SDGHGKTLSH VVQDRVERDY TIEDLEEWTE YRVQVQAFNA IGSGPWSQTV VGRTRESVPS
  1201  SGPTNVSALA TTSSSMLVRW SEVPEADRNG LVLGYKVMYK EKDSDTQPRF WLVEGNSSRS
  1261  AQLTGLGKYV LYEVQVLAFT RIGDGSPSHP PILERTLDDV PGPPMGILFP EVRTTSVRLI
  1321  WQPPAAPNGI ILAYQITHRL NTTTANTATV EVLAPSARQY TATGLKPESV YLFRITAQTR
  1381  KGWGEAAEAL VVTTEKRDRP QPPSRPMVQQ EDVRARSVLL SWEPGSDGLS PVRYYTIQTR
  1441  ELPSGRWALH SASVSHNASS FIVDRLKPFT SYKFRVKATN DIGDSEFSEE SESLTTLQAA
  1501  PDEAPTILSV TPHTTTSVLI RWQPPAEDKI NGILLGFRIR YRELLYEGLR GFTLRGINNP
  1561  GATWAELTSM YSMRNLSRPS LTQYELDNLN KHRRYEIRMS VYNAVGEGPS SPPQEVFVGE
  1621  AVPTAAPRNV VVHGATATQL DVTWEPPPLD SQNGDIQGYK IYFWEAQRGN LTERVKTLFL
  1681  AENSVKLKNL TGYTAYMVSV AAFNAAGDGP RSTPTQGQTQ QAAPSAPSSV KFSELTTTSV
  1741  NVSWEAPQFP NGILEGYRLV YEPCSPVDGV SKIVTVDVKG NSPLWLKVKD LAEGVTYRFR
  1801  IRAKTFTYGP EIEANVTTGP GEGAPGPPGV PIIVRYSSAI AIHWSSGDPG KGPITRYVIE
  1861  ARPSDEGLWD ILIKDIPKEV SSYTFSMDIL KPGVSYDFRV IAVNDYGFGT PSSPSQSVPA
  1921  QKANPFYEEW WFLVVIALVG LIFILLLVFV LIIRGQSKKY AKKTDSGNSA KSGALGHSEM
  1981  MSLDESSFPA LELNNRRLSV KNSFCRKNGL YTRSPPRPSP GSLHYSDEDV TKYNDLIPAE
  2041  SSSLTEKPSE ISDSQGSDSE YEVDSNHQKA HSFVNHYISD PTYYNSWRRQ QKGISRAQAY
  2101  SYTESDSGEP DHTTVTNSTS TQQGSLFRPK ASRTPTPQNP PNPPSQQSTL YRPPSSLAPG
  2161  SRAPIAGFSS FV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SDK2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.32
Highest tissue expression: 9.1 nTPM

Expression across tissuesHPA

Tissue

testis: 9.1 nTPM
cervix: 5.2 nTPM
spleen: 2.5 nTPM
fallopian tube: 2.3 nTPM
spinal cord: 2.1 nTPM
hypothalamus: 1.9 nTPM

Single-cell type

sertoli cells: 221 nCPM
ependymal cells: 156 nCPM
extravillous trophoblasts: 149 nCPM
retinal horizontal cells: 146 nCPM
thymocytes: 103 nCPM
neuroendocrine cells: 103 nCPM

Immune cell

naive B-cell: 0.5 nTPM
plasmacytoid DC: 0.5 nTPM
memory B-cell: 0.1 nTPM
naive CD4 T-cell: 0.1 nTPM
naive CD8 T-cell: 0.1 nTPM
basophil: 0 nTPM

Brain region

pons: 20 nTPM
cerebral cortex: 17 nTPM
medulla oblongata: 14 nTPM
basal ganglia: 14 nTPM
thalamus: 13 nTPM
white matter: 13 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.35
gnomAD pLI: 0
gnomAD missense Z: 2.68
DepMap mean gene effect: -0.13
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SDK2 as an antibody target. Whether an autoantibody or antibody against SDK2 could matter depends on whether native SDK2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SDK2 is annotated at the cell surface, where native SDK2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SDK2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...